LIXTE Biotechnology Holdings, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Commitments and Contingencies (Details Narrative)

Commitments and Contingencies (Details Narrative)																	3 Months Ended	12 Months Ended
Commitments and Contingencies (Details Narrative)	Mar. 20, 2021 USD ($)	Jan. 18, 2021 USD ($)	Dec. 21, 2020 USD ($)	Aug. 12, 2020 USD ($) shares	Aug. 01, 2020 USD ($) shares	Jul. 15, 2020 USD ($) shares	Feb. 18, 2020 USD ($)	May 22, 2019 USD ($)	Sep. 12, 2018 USD ($)	Aug. 20, 2018 USD ($)	Apr. 05, 2018 USD ($)	Apr. 05, 2018 EUR (€)	Apr. 02, 2018	Mar. 22, 2018 USD ($)	Sep. 14, 2015 USD ($)	Dec. 24, 2013 USD ($)	Jun. 30, 2020 USD ($)	Dec. 31, 2020 USD ($) shares	Dec. 31, 2019 USD ($) shares
Research and development costs																		$ 1,223,676	$ 820,906
Stock options granted to purchase common stock, issued \| shares																		200,000	133,333
Stock options grant date fair value								$ 189,060										$ 100,000
NDA Consulting Corp [Member]
Agreement term																1 year
Consulting and advisory fee																$ 4,000		16,000	$ 16,000
Clinical Trial Research Agreement [Member]
Research and development costs																		102,944
Clinical Trial Research Agreement [Member] \| Moffitt Cancer Center and Research Institute Hospital Inc [Member]
Payments for clinical trial																		41,142	45,093
Aggregate commitments expected																		616,000
Collaboration Agreement [Member]
Research and development costs																		130,882
Advance amount related to milestone payment																	$ 87,471	43,411	87,471
Collaboration Agreement [Member] \| Subsequent Event [Member]
Advance amount related to milestone payment	$ 23,802
Collaboration Agreement [Member] \| Grupo Espanol de Investigacion en Sarcomas [Member]
Advance amount related to milestone payment							$ 43,411
Aggregate commitments expected																		4,614,000
Collaboration Agreement [Member] \| BioPharmaWorks LLC [Member]
Amount charges to operations																		131,650
Consulting and advisory fee															$ 10,000
Reimbursed expense																		11,650	100,000
Clinical Trial Agreement [Member]
Aggregate commitments expected																		$ 5,230,000
Aggregate commitments expected, description																		The Company's aggregate commitments pursuant to the aforementioned clinical trial agreements, less amounts previously paid to date under these agreements, totaled approximately $5,230,000 as of December 31, 2020, consisting of approximately $4,614,000 relating to the GEIS clinical trial and approximately $616,000 relating to the Moffit clinical trial, which are expected to be incurred over the next five years through December 31, 2025.
Clinical Trial Agreement [Member] \| City of Hope [Member] \| Subsequent Event [Member]
Aggregate commitments expected, description		The Company estimates that from 24 to 30 patients will be needed to complete this clinical trial, at an estimated cost of $2,500,000 to $2,900,000, respectively. If a significant number of patients fail during the dose-escalation process, an increase of up to 12 patients would likely be necessary, at an estimated additional cost of $800,000.
Additional estimated commitments cost		$ 800,000
Clinical Trial Agreement [Member] \| City of Hope [Member] \| Subsequent Event [Member] \| Minimum [Member]
Aggregate commitments expected		2,500,000
Clinical Trial Agreement [Member] \| City of Hope [Member] \| Subsequent Event [Member] \| Maximum [Member]
Aggregate commitments expected		$ 2,900,000
Other Clinical Agreements [Member]
Aggregate commitments expected																		$ 300,000
Other Clinical Agreements [Member] \| Minimum [Member]
Research and development costs																		600,000
Other Clinical Agreements [Member] \| Maximum [Member]
Research and development costs																		700,000
Work Order Agreement [Member]
Research and development costs																		75,788
Aggregate commitments expected																		874,000
Work Order Agreement [Member] \| Theradex Systems, Inc [Member]
Research and development costs									$ 954,000									18,663	51,586
Payment expected dividend for pass-through costs, description									The clinical trial began in April 2019 and the first patient was entered into the clinical trial in July 2019. At the current rate of accrual, the trial would be completed over a period of four years from its initiation, with the final analysis and reporting expected by July 2023. Costs under this work order agreement are estimated to be approximately $954,000, with such payments expected to be divided approximately 94% to Theradex for services and approximately 6% for payments for pass-through costs.
Material Transfer Agreement [Member] \| INSERM [Member] \| Maximum [Member] \| Development Milestones [Member]
Milestone payments														$ 1,750,000
Material Transfer Agreement [Member] \| INSERM [Member] \| Maximum [Member] \| Commercial Milestones [Member]
Milestone payments														$ 6,500,000
Consulting Agreement with Liberi Life Consultancy BV [Member]
Agreement term													2 years
Payment of a fixed, one-time retainer											$ 18,348
Net payments of sales of products or licensing activities, percentage											2.50%	2.50%
Consulting Agreement with Liberi Life Consultancy BV [Member] \| EURO [Member]
Payment of a fixed, one-time retainer \| €												€ 15,000
Consulting Agreement [Member]
Amount charges to operations																		2,294	9,174
Unamortized balance of the retainer payment																			9,174
Exclusive License Agreement [Member]
Amount charges to operations																		$ 25,001	80,669
Royalties description																		The Company will be obligated to pay Moffitt earned royalties of 4% on worldwide cumulative net sales of royalty-bearing products, subject to reduction to 2% under certain circumstances, on a quarterly basis, with a minimum royalty payment of $50,000 in the first four years after sales commence, and $100,000 in year five and each year thereafter, subject to reduction by 40% under certain circumstances relating to the status of Valid Claims, as such term is defined in the License Agreement.
Exclusive License Agreement [Member] \| First Four Years [Member]
Minimum payments for royalties																		$ 50,000
Exclusive License Agreement [Member] \| Five Years and Thereafter [Member]
Minimum payments for royalties																		100,000
Exclusive License Agreement [Member] \| Moffitt Cancer Center and Research Institute Hospital Inc [Member]
Non-refundable license issue fee										$ 25,000
Annual license maintenance fee										25,000
Payments on non-refundable milestone										$ 1,897,000
Percentage of milestone										40.00%
Employment Agreement [Member] \| General and Administrative Expense [Member]
Charges for salary																		62,500
Employment Agreement [Member] \| Dr. John Kovach [Member]
Annual salary						$ 250,000												45,000	60,000
Employment Agreement [Member] \| Eric Forman [Member]
Annual salary						$ 120,000
Stock options granted to purchase common stock, issued \| shares						350,000
Employment Agreement [Member] \| Eric Forman [Member] \| General and Administrative Expense [Member]
Charges for salary																		30,000
Consulting fee																		38,000	48,000
Employment Agreement [Member] \| Dr. James Miser [Member] \| General and Administrative Expense [Member]
Charges for salary																		62,500
Employment Agreement [Member] \| Dr. James Miser [Member]
Annual salary					$ 150,000
Stock options granted to purchase common stock, issued \| shares					500,000
Stock options grant date fair value					$ 143,163
Employment Agreement [Member] \| Robert N. Weingarten [Member]
Annual salary				$ 120,000
Stock options granted to purchase common stock, issued \| shares				350,000
Stock options grant date fair value				$ 100,214
Employment Agreement [Member] \| Robert N. Weingarten [Member] \| General and Administrative Expense [Member]
Charges for salary																		46,451
Consulting fee																		$ 79,995	$ 80,380
Master Service Agreement [Member] \| Foundation for Angelman Syndrome Therapy [Member]
Percentage of proceeds agree to pay under agreement				5.00%
Maximum amount received under agreement				$ 250,000
Service Agreement [Member] \| IRTH Communications, LLC [Member]
Consulting and advisory fee			$ 7,500
Stock options grant date fair value			$ 100,000